Spero Therapeutics Inc (SPRO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Spero Therapeutics Inc (SPRO) has a cash flow conversion efficiency ratio of 0.658x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($17.42 Million) by net assets ($26.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Spero Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Spero Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Spero Therapeutics Inc for a breakdown of total debt and financial obligations.
Spero Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Spero Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tribeca Global Natural Resources Ltd
AU:TGF
|
-0.103x |
|
Prosafe SE
OL:PRS
|
-0.021x |
|
UBM Development AG
VI:UBS
|
-0.015x |
|
Blaize Holdings, Inc.
NASDAQ:BZAI
|
-19.079x |
|
Daishin Balance No.6 Special Purpose Acquisition Co. Ltd
KQ:307750
|
0.040x |
|
Peninsula Energy Ltd
AU:PEN
|
-0.085x |
|
Bank Mnc Internasional Tbk
JK:BABP
|
-0.183x |
|
Fortinova Fastigheter AB Series B
ST:FNOVA-B
|
0.015x |
Annual Cash Flow Conversion Efficiency for Spero Therapeutics Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Spero Therapeutics Inc from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see Spero Therapeutics Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $46.12 Million | $-23.44 Million | -0.508x | -64.67% |
| 2023-12-31 | $106.89 Million | $-32.99 Million | -0.309x | -203.18% |
| 2022-12-31 | $75.93 Million | $-7.73 Million | -0.102x | +86.03% |
| 2021-12-31 | $88.29 Million | $-64.35 Million | -0.729x | -12.07% |
| 2020-12-31 | $132.04 Million | $-85.87 Million | -0.650x | +3.04% |
| 2019-12-31 | $74.57 Million | $-50.02 Million | -0.671x | -96.11% |
| 2018-12-31 | $115.86 Million | $-39.62 Million | -0.342x | +25.71% |
| 2017-12-31 | $84.96 Million | $-39.11 Million | -0.460x | +89.89% |
| 2016-12-31 | $6.36 Million | $-28.96 Million | -4.553x | -112.18% |
| 2015-12-31 | $-257.00K | $-9.61 Million | 37.385x | -- |
About Spero Therapeutics Inc
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including … Read more